Bristol-Myers To Nearly Double Japan Sales Staff By 2012
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb says it plans to nearly double its staff of sales representatives in Japan or more by 2012. The company, which now has about 460 medical representatives in Japan, plans to add another 300 to reach 760, primarily to market its cancer drugs expected to be available as early as 2011. The company said the added staff also would focus on marketing thrombosis and hepatitis C drugs during that period. Other products are expected to come on line in Japan by 2016. (Click here for more - a subscription may be required)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.